Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07236320Not ApplicableCompleted

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Role: lead

NCT06775652Phase 3Completed

Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC

Role: lead

NCT06169930Completed

Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy

Role: lead

NCT05617352Completed

The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study

Role: lead

NCT05604664Completed

Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc

Role: lead

NCT05604950Completed

Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years

Role: lead

NCT05570487Unknown

RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDY

Role: lead

All 7 trials loaded